Steve Abella

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Jeff P. Sharman, Michael Hawkins, Kathryn S. Kolibaba et al. · Blood · 2015 · 184 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Epidermal Abnormalities May Distinguish Type 2 from Type 1 and Type 3 of Gaucher Disease

Ellen Sidransky, Robert Lee, Leon A. Metlay et al. · Pediatric Research · 1996 · 96 citations

Life Sciences, Dermatology, Genetics +13

Cyclosporin A toxicity: MRI appearance of the brain

M Pace, Thomas L. Slovis, Jill Kelly et al. · Pediatric Radiology · 1995 · 63 citations

Medicine, Neurology, Pharmacology +11

FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).

Joaquim Bellmunt, Joel Picus, Manish Kohli et al. · Journal of Clinical Oncology · 2018 · 24 citations

Medicine, Oncology, Pharmacology +16

Chromosome analyses of 16 cases of Wilms tumor: different pattern in unfavorable histology

Edward Peres, Süreyya Savaşan, Barbara Cushing et al. · Cancer Genetics and Cytogenetics · 2003 · 23 citations

Life Sciences, Genetics, Oncology +12